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reticulum and Golgi apparatus as well as co-expressed 
with its substrate CCL2. In aged APP transgenic Tg2576 
mice, both isoQC and CCL2 mRNA levels are up-regu-
lated and isoQC and CCL2 proteins were found to be co-
induced in Abeta plaque-associated reactive astrocytes. 
Also, in mouse primary astrocyte culture, a simultaneous 
up-regulation of isoQC and CCL2 expression was revealed 
upon Abeta and pGlu-Abeta stimulation. In brains of AD 
patients, the expression of isoQC and CCL2 mRNA and 
protein is up-regulated compared to controls and correlates 
with pGlu-Abeta load and with the decline in mini-mental 
state examination. Our observations provide evidence for a 
dual involvement of isoQC in AD pathogenesis by cataly-
sis of pGlu-Abeta and pGlu-CCL2 formation which mutu-
ally stimulate inflammatory events and affect cognition. 
We conclude that isoQC inhibition may target both major 
pathological events in the development of AD.
Introduction
Amyloid pathology and neuroinflammation including 
activation of glial cells are key hallmarks of the neuropa-
thology in brains of Alzheimer’s disease (AD) patients. 
Both Abeta peptides and pro-inflammatory cytokines/
chemokines are reported to interfere with neuronal sur-
vival and with proper synaptic function, resulting in 
cognitive decline [6, 20, 21, 62]. The relation between 
the actual clinical status of the patient and the degree of 
neuropathology can be assessed by testing cognitive func-
tion and by imaging techniques monitoring hippocampal 
shrinkage, Abeta deposition and microglial activation 
[26, 29, 55]. Abeta peptides are generated by proteolyti-
cal processing of the amyloid precursor protein (APP) 
and may undergo post-translational modification such 
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as N-terminal truncation and subsequent cyclization of 
N-terminal glutamate (Glu) into pyroglutamate (pGlu) 
[43, 46, 47, 56]. The resulting pGlu-Abeta peptides (1) 
are major constituents of Abeta deposits in sporadic and 
familial AD [33, 40, 41, 46], (2) possess a high aggrega-
tion velocity [13, 18, 31, 44, 51, 54], (3) display resist-
ance to degradation by peptidases [45] and (4) are particu-
larly neurotoxic to primary neurons, neuronal cell lines 
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and neurons of APP transgenic animals in vivo [1, 2, 38, 
44, 61]. Interestingly, pGlu-modified Abeta peptides in 
brains of AD patients and transgenic mouse models were 
reported to be closely associated with [11C]Pittsburgh 
Compound-B (PIB) autoradiographic signals [28].
The pGlu-Abeta peptide modification has been dem-
onstrated to be catalyzed by glutaminyl cyclase (QC) 
in vitro [50] and in vivo [11, 12, 49, 53]. Recently, 
we observed robust QC expression in mouse and 
human brain in AD-vulnerable subcortical regions 
such as nucleus basalis Meynert, locus coeruleus and 
Edinger–Westphal nucleus [35] and in a subpopula-
tion of neocortical neurons and of GABAergic interneu-
rons in hippocampus [15, 16]. Chronic pharmaco-
logical inhibition or genetic ablation of QC activity 
in animal models of AD resulted in reduced pGlu-Abeta 
peptide generation and in ameliorated behavioral deficits 
[2, 22, 53], while QC overexpression aggravated neuropa-
thology and cognitive dysfunction in transgenic mice [22].
Recently, a Golgi-resident isoenzyme of QC with iden-
tical enzymatic characteristics was discovered [10, 59]. In 
cell-free assays, both enzymes convert a variety of sub-
strates with similar kinetics and are inhibited by a number 
of inhibitors from different chemical classes at comparable 
Ki values [59]. However, based on the cell type-specific 
expression and subcellular localization, QC and isoQC 
appear to have distinct physiological substrate profiles. 
For example, isoQC—but not QC—catalyzes the pGlu 
modification of the monocyte chemoattractant protein-1 
(MCP-1; also designated CCL2) and thereby stimulates 
monocytic infiltration into the peritoneum of mice in the 
thioglycollate-induced peritonitis model [8]. CCL2 lack-
ing the pGlu modification has reduced chemoattractant 
activity and is less resistant to proteolytical degradation 
Fig. 1  Expression of isoQC in mouse brain. a The enzyme isoQC is 
expressed almost ubiquitously in numerous neocortical, hippocampal, 
subcortical and cerebellar brain structures of wild-type mouse brain 
at 4 months of age as evidenced by immunohistochemical labeling in 
sagittal sections. b This labeling is highly specific as shown by the 
absence of staining in brain tissue of isoQC knock-out mice. On the 
other hand, in QC knock-out brain tissue the isoQC labeling is not 
affected. c In coronal sections, some brain regions with particularly 
high expression levels of isoQC can be distinguished. These include 
piriform 1 entorhinal 3 and pyramidal layer V 6 cortices, hippocam-
pal structures such as indusium griseum 2, Cornu ammonis 1–4 and 
dentate gyrus 5, as well as habenular 4 and Edinger–Westphal 7 
nuclei, locus coeruleus 8, cochlear nucleus 9 and Purkinje cells of 
the cerebellum 10. d At higher magnification labeled cells in all these 
brain regions appear to have a neuronal shape and size. 1 piriform 
cortex, 2 indusium griseum, 3 entorhinal cortex, 4 habenular nucleus, 
5 hippocampus, 6 parietal cortex, 7 Edinger–Westphal ncl., 8 locus 
coeruleus, 9 cochlear nucleus, 10 Purkinje cells
Table 1  Cocktails of antibodies 
used for double and triple 
labeling immunohistochemistry
Secondary antibodies were all 
from Dianova and used at a 
dilution of 1:400 (biotinylated) 
and 1:200 (fluorochromated)
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by aminopeptidases [8]. Recent studies demonstrated that 
isoQC-catalyzed pGlu-CCL2 also contributes to inflam-
matory tissue damage in mouse models of septic arthritis 
and non-alcoholic fatty liver disease [9, 19]. Since the tis-
sue damage is less severe in isoQC knock-out mice and 
has been shown to be ameliorated by isoQC inhibitors, it 
points towards a role of isoQC in chronic inflammatory 
processes.
In AD, CCL2 was also shown to play a dominant role 
in chronic inflammation [58] and to be associated with a 
faster rate of cognitive decline at early stages of the disease 
[60]. Likewise, CCL2 overexpression accelerated Abeta 
oligomer and diffuse plaque formation and caused deficits 
in spatial and working memory in mouse models of AD 
[25, 63], while expression of a dominant negative CCL2 
variant ameliorated Abeta pathology and reduced memory 
impairments [24]. Chronic neuroinflammation triggered by 
a variety of stimuli including—but not limited to—Abeta 
peptide aggregates was shown to contribute to cognitive 
decline in AD patients [32, 42].
So far, the enzymatic mechanisms of pGlu-CCL2 for-
mation in brain, the brain region and cell type-specific 
expression pattern of isoQC, its subcellular localization 
and correlation with Abeta pathology in brains of trans-
genic mice and AD patients are not yet known and were 
therefore the subject of this study. Collectively, we here 
report for the first time a role for isoQC in CCL2 matu-
ration and bioactivity in brain which may contribute to 




Brain tissue of wild-type and APP transgenic Tg2576 mice 
at the postnatal age of 4 and 17 months was used for immu-
nohistochemical, ELISA and quantitative reverse tran-
scriptase PCR (qRT-PCR) analyses. IsoQC knock-out mice 
described in Cynis et al. [8] served as negative control for 
the specificity of the isoQC antibodies employed.
For immunohistochemistry, mice were anesthetized with 
pentobarbital and transcardially perfused with 25 ml of 
phosphate-buffered saline (PBS, 0.01 M; pH 7.4) followed 
by perfusion with 25 ml of 4 % paraformaldehyde in phos-
phate buffer (PB, 0.1 M; pH 7.4). Brains were removed 
from the skull and post-fixed by immersion in the same fixa-
tive overnight at 4 °C. After cryoprotection in 30 % sucrose 
in 0.1 M PB for 3 days, brains were snap-frozen in n-hexane 
at −68 °C and stored at −20 °C. Coronal sections (30 µm) 
were cut on a sliding microtome and collected in 0.1 M PB.
For biochemical analyses, mice were sacrificed by 
decapitation at the postnatal age indicated, brains were 
removed from the skull, and neocortex was prepared, snap-
frozen in liquid nitrogen and stored at −80 °C pending 
qRT-PCR or ELISA analyses.
isoQC and CCL2 antibodies
Since the specificity of the immunohistochemical isoQC 
labeling is critical for this study, we tested a number of 
Table 2  Human brain tissue used for biochemistry and correlation analyses
AD Alzheimer’s disease, PMD postmortem delay, Co control, COD cause of death, MMSE Mini-Mental State Examination, CERAD Consortium 
to Establish a Registry for Alzheimer’s Disease, NIA National Institute on Aging




















Control Co1 2.5 Female 86 1,145 Pulmonary fibrosis III 27/30 0 Not met Not met
Co2 2.5 Female 87 1,120 Pneumonia/cancer IV 30/30 0 Not met Not met
Co3 2.75 Female 75 1,110 Pulmonary embolus III 29/30 0 Not met Not met
Co4 3.0 Male 82 1,240 Renal failure/COPD III 26/30 A Not met Not met
Co5 1.66 Male 78 1,460 Lung cancer/heart failure I 28/30 0 Not met Not met
Co6 5.5 Male 89 1,275 Respiratory distress/COPD II 30/30 0 Not met Not met
Co7 4.75 Male 86 1,400 Cardiac arrest I 28/30 0 Not met Not met
Mean 3.25 3/4 83.3 1,250
AD AD1 1.83 Female 84 1,080 End-stage AD VI 0/30 C Definite AD High
AD2 1.5 Female 85 940 Breast cancer/end-stage AD VI 2/30 C Definite AD High
AD3 3.16 Male 80 1,000 End-stage AD VI 1/30 C Definite AD High
AD4 2.25 Male 78 1,120 End-stage AD VI 7/30 C Definite AD High
AD5 2.5 Male 87 1,100 End-stage AD VI 13/30 C Definite AD High
Mean 2.25 2/3 82.8 1,048
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Fig. 2  Neuronal isoQC expres-
sion, subcellular localization 
and co-expression of CCL2 
in mouse brain and primary 
neurons. a IsoQC was strictly 
co-localized with the neuronal 
marker HuC/D in brain sections 
of 17-month-old wild-type mice 
demonstrating a neuron-specific 
expression. Cells which did not 
display HuC/D immunoreactiv-
ity were also negative for isoQC 
labeling (arrows). b IsoQC 
was co-localized with cellular 
compartment markers calreti-
culin and syntaxin-6, consistent 
with a subcellular localization 
in endoplasmic reticulum and 
Golgi apparatus. c The putative 
isoQC substrate CCL2 was 
found to be co-expressed by 
isoQC-immunoreactive neurons 
in cortex of wild-type mice 
(top) and in primary neuronal 
cultures (bottom). d The conver-
sion of CCL2 by recombinant 
isoQC was analyzed in a kinetic 
assay. The progress curve (black 
trace) was in accordance with a 
curve modeled according to the 
integrated form of the Michae-
lis–Menten equation (red trace), 
enabling the determination 
of the kinetic parameters KM 
(19.8 ± 0.4 μM) and kcat 
(0.76 ± 0.01 s−1)
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isoQC antibodies in brain tissue of wild-type, QC knock-
out and isoQC knock-out mice. The antiserum 3285 (Probi-
odrug, Halle/S., Germany) allowed for the specific immu-
nohistochemical detection of isoQC in mouse brain. This 
staining was completely absent in brains of isoQC knock-
out mice, but not in brains of QC knock-out mice (Fig. 1).
Additionally, different anti-CCL2 antibodies derived 
from mouse and goat, respectively, were tested. The goat 
anti-CCL2 antiserum sc-1784 (St. Cruz) and the mouse 
anti-CCL2 antibody (clone 4B8; Probiodrug, Halle/Saale, 
Germany) showed a distinct staining pattern for CCL2 
around nuclei of mouse primary neurons as well as of 
neurons in mouse brain tissue. The other tested antibod-
ies displayed more diffuse and undifferentiated staining of 
brain sections or unspecific labeling of blood capillaries. 
In human brain tissue, the goat antiserum sc-1784 and the 
Fig. 3  Regulation of isoQC and 
CCL2 expression in Tg2576 
mice. a The neocortical isoQC 
and CCL2 mRNA levels were 
increased by 135 and 55 %, 
respectively, in 17-month-old 
APP transgenic Tg2576 mice 
(black bars) compared to wild-
type littermates (white bars) 
as demonstrated by qRT-PCR 
analyses. Additionally, GFAP 
mRNA levels were increased by 
115 %, indicating astrogliosis 
in Tg2576 mice. The isoQC 
and pGlu-CCL2 protein levels, 
however, were not affected 
in Tg2576 mice as measured 
by Western blot analysis and 
ELISA, respectively. b In 
17-month-old wild-type (wt) 
and APP transgenic Tg2576 
mice (tg) there was a predomi-
nantly neuronal expression of 
isoQC and CCL2 (green immu-
nofluorescence) as revealed by 
co-expression of HuC/D (red 
immunofluorescence). The 
asterisks indicate the position of 
Abeta plaques in Tg2576 tissue. 
c In addition, aged Tg2576 
mice—but not wild-type lit-
termates—displayed astrocytic 
expression of isoQC and CCL2 
in proximity of Abeta deposits 
following a gradient from the 
core towards the periphery of 
plaques (I, within plaque core 
diameter; II, double plaque 
core diameter; III, triple plaque 
core diameter). d The astro-
cytic co-expression (arrows) of 
isoQC and CCL2 in proximity 
of Abeta plaques (asterisks) is 
visualized by the co-expres-
sion of the astrocyte marker 
GFAP (red immunofluores-
cence). *p < 0.05, **p < 0.01, 
***p < 0.001
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mouse monoclonal antibody MAB2791 (R&D Systems) 
demonstrated distinct neuronal CCL2 labeling comparable 
to the staining pattern observed in mouse brain.
Based on specificity and the superior signal-to-back-
ground ratio, the rabbit anti-isoQC antiserum 3285 and 
the goat anti-CCL2 antiserum sc-1784 were selected for 
immunohistochemistry in mouse brain tissue and the rabbit 
anti-isoQC antiserum 3285 as well as the monoclonal anti-
CCL2 antibody MAB2791 was used in human brain tissue.
isoQC immunohistochemistry in mouse brain
Immunohistochemistry to detect isoQC was performed 
using the affinity-purified rabbit antiserum 3285 at a dilu-
tion of 1:500. After inactivation of endogenous peroxidase 
with 0.6 % H2O2 in 0.1 M TBS for 15 min and blocking 
of unspecific binding sites with 5 % normal goat serum in 
TBS containing 0.3 % Triton-X100, brain sections were 
incubated in the same solution with the primary antibody 
Fig. 3  continued
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at 4 °C overnight in a humid chamber on a shaker. The fol-
lowing day, sections were incubated with secondary bioti-
nylated goat anti-rabbit antibodies (Dianova; 1:400) in 
TBS-2 % bovine serum albumin (BSA) for 60 min at room 
temperature followed by the ABC method which comprised 
incubation with complexed streptavidin-biotinylated horse-
radish peroxidase (Invitrogen). Incubations were sepa-
rated by washing steps (3 times 5 min in TBS). The isoQC 
immunoreaction was visualized by incubation with 4 mg 
3,3′-diaminobenzidine (DAB) and 2.5 µl H2O2 per 5 ml 
Tris buffer (0.05 M, pH 7.6) for 1–2 min.
Double immunofluorescent labeling procedures
To reveal (1) the cell type-specific expression, (2) the intra-
cellular localization and (3) the co-localization of isoQC 
with its putative substrate CCL2, the rabbit anti-isoQC 
antiserum 3285 was used in combination with mouse 
monoclonal antibodies or a polyclonal antiserum from 
goat or chicken directed against neuron-, astrocyte- and 
compartment-specific marker proteins and against CCL2, 
respectively (see Table 1). Brain sections were incubated 
with cocktails of primary antibodies overnight at 4 °C. On 
the next day, sections were washed three times with TBS 
and were then incubated with biotinylated donkey anti-
rabbit, 1:400 and Cy3-conjugated donkey anti-mouse, 
-goat and -chicken, 1:200 (Dianova) secondary antibod-
ies, respectively, followed by Cy2-conjugated streptavidin 
1:100 (Dianova) for 60 min at room temperature. After 
mounting the brain sections on microscope slides, cellular 
nuclei were counterstained with ToPro3 (1:10,000; Life 
Technologies).
Confocal laser scanning microscopy
Confocal laser scanning microscopy (LSM 510, Zeiss, 
Oberkochen, Germany) was performed to reveal co-local-
ization of isoQC and intracellular compartment markers 
as well as with CCL2. For Cy2-labeled antigens (green 
fluorescence), an argon laser with 488 nm excitation and 
510 nm emission wavelength was used applying a low-
range band pass (505–530 nm). For Cy3-labeled antigens, 
a helium–neon laser with 543 nm excitation and 570 nm 
emission was used applying high-range band pass (560–
615 nm). The nuclear staining compound ToPro3 was visu-
alized by excitation at 642 nm and emission at 661 nm.
Mouse primary neuronal and astrocyte cultures
Primary neuronal cell cultures were derived from fetal 
mouse brain at gestation day 16 as described by Löffner 
et al. [27]. After 3 days in vitro, cultures were treated with 
10 µM cytosine-1-β-d-arabinofuranoside to suppress the 
growth of dividing cells, mainly of astroglial origin. Astro-
cyte-rich primary cell cultures were derived from brains 
of newborn mice according to Löffner et al. [27] and were 
maintained in DMEM-based medium. Cells were cultured 
at 37 °C in a humidified atmosphere with 95 % air/5 % CO2 
and the medium was renewed every 1–3 days. After 7 days 
in culture, astrocytes were incubated in Abeta (5 µM), pGlu-
Abeta (5 µM), LPS (1 µg/ml medium; O55:B5, Sigma), 
IFN-γ (20 ng/ml medium; Sigma) or a combination of LPS/
IFN-γ for 12, 24, 48 and 72 h, respectively. Abeta pep-
tides were synthesized in 50 µmol scale on Fmoc-Val/Ala-
NovaSyn-TGA resin (0.15 mmol/g) using an automated 
Symphony Synthesizer (Rainin) as described in detail in 
[51]. The crude peptides were dissolved in HFIP for pre-
parative HPLC and further purified by RP-HPLC [51]. Pep-
tide purity and identity were confirmed by analytical HPLC 
(150 × 4.6, 5 µ Source or Gemini) and matrix-assisted laser 
desorption ionization mass spectroscopy (MALDI-MS). 
Prior to use, the peptides were dissolved in 1 mM HFIP and 
incubated at room temperature for 2 h to solubilise peptides 
and to monomerise β-sheet protein aggregates. Following 
evaporation of HFIP the peptides were dissolved in Optimen 
medium and diluted to the final concentration indicated.
Human brain tissue
Case recruitment and characterization of human brain 
tissue
Case recruitment and autopsy were performed in accord-
ance with guidelines effective at Banner Sun Health 
Research Institute Brain Donation Program of Sun City, 
AZ, USA [4]. The required consent was obtained for all 
cases. The definite diagnosis of AD for all cases used in 
this study was based on the presence of neurofibrillary 
tangles and neuritic plaques in the hippocampal formation 
and neocortical areas and met the criteria of the National 
Institute on Aging (NIA) and the Consortium to establish 
a registry for AD (CERAD) [34]. Brain tissue of tempo-
ral cortex (Brodmann Area 22) from 6 controls and 6 age-
matched AD cases was used for isoQC, CCL2, GFAP and 
pGlu-Abeta immunohistochemistry. Additionally, for bio-
chemical analyses, temporal cortex (Brodmann Area 22) of 
7 control cases and 5 AD cases with a very short postmor-
tem interval of 1.5–5.5 h and a thorough clinical characteri-
zation was used (Table 2). Anatomical structures and cor-
tical layers were identified using consecutive Nissl-stained 
sections and the atlas of the human brain [30].
Tissue preparation
For immunohistochemistry, 15-mm-thick tissue blocks 
were prepared in the frontal plane according to the atlas of 
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the human brain [30] and were fixed in 4 % paraformalde-
hyde in 0.1 M PBS, pH 7.4 for 3–4 days. Areas containing 
the regions of interest were cryoprotected in 30 % sucrose 
in 0.1 M PBS, pH 7.4. Series of 30-µm-thick sections were 
cut on a freezing microtome and collected in PBS contain-
ing 0.1 % sodium azide.
For biochemical analyses including Abeta and CCL2 
ELISAs, and for quantitative RT-PCR to detect isoQC 
and CCL2 transcripts, unfixed temporal cortex tissue with 
a short postmortem interval was stored at −80 °C (see 
Table 2). Brain tissue (10 % w/v) was homogenized in TBS 
(20 mM Tris, 137 mM NaCl, pH 7.6) containing protease 
inhibitor cocktail (Complete Mini, Roche), sonicated and 
then centrifuged at 75,500×g for 1 h at 4 °C and the super-
natant was stored at −80 °C. Abeta peptides were sequen-
tially extracted with TBS/1 % Triton X-100 (TBS/triton 
fraction), 2 % SDS in distilled water (SDS fraction), and 
70 % formic acid (FA fraction). The combined SDS and FA 
fractions were considered as the insoluble pool of Abeta. 
For determination of CCL2, brain tissue was homog-
enized (Precellys homogenizer, Peqlab) in the threefold 
volume (w/v) of ice-cold ELISA blocker (Thermo Scien-
tific) containing protease inhibitors. The homogenate was 
centrifuged (10 min, 15,000×g), the supernatant removed 
and subjected to another centrifugation step (30 min, 
25,000×g). The final supernatant was shock-frozen and 
stored at −80 °C.
Immunohistochemistry of human brain tissue
Nissl staining
Coronal sections of the human hippocampus were mounted 
on gelatin-coated slides and stained in 0.1 % cresyl violet 
according to standard protocols.
Single labeling isoQC and CCL2 immunohistochemistry
All immunohistochemical procedures were performed 
on free-floating brain sections. Immunohistochemistry to 
detect isoQC and CCL2 in human brain was performed 
using the rabbit anti-isoQC antiserum 3285 (1:500) and 
the mouse monoclonal CCL2 antibody MAB2791 (1:500), 
respectively. Brain sections were treated with 2 % H2O2 in 
60 % methanol for 1 h, to abolish endogenous peroxidase 
activity. Unspecific staining was blocked in PBS-T con-
taining 2 % BSA, 0.3 % milk powder and 0.5 % normal 
donkey serum before incubating brain sections with the 
primary antibodies at 4 °C overnight. The following day, 
sections were incubated with secondary biotinylated don-
key anti-rabbit or donkey anti-mouse antibodies (Dianova; 
1:1,000) for 60 min at room temperature followed by the 
ABC method which comprised incubation with complexed 
streptavidin-biotinylated horseradish peroxidase. Incuba-
tions were separated by washing steps (3 times 5 min in 
PBS-T). Binding of peroxidase was visualized by incu-
bation with 2 mg DAB, 20 mg nickel ammonium sulfate 
and 2.5 µl H2O2 per 5 ml Tris buffer (0.05 M; pH 8.0) for 
1–2 min, resulting in black labeling.
Double and triple labeling immunohistochemistry
Simultaneous immunohistochemical double and triple labe-
ling of isoQC and its putative substrate CCL2 in combina-
tion with the astrocyte marker GFAP or with pGlu-Abeta 
were performed by incubations of brain slices in cocktails 
of primary antibodies from different species (Table 1) at 
4 °C overnight following the procedure for mouse brain 
described above.
qRT-PCR for isoQC and CCL2
Mouse and human brain tissue samples and cultured pri-
mary mouse astrocytes were homogenized using a Precellys 
homogenizer with 1.4-mm ceramic beads (5,000 rpm, 
30 s, Peqlab). RNA was isolated using the NucleoSpin 
RNA II kit (Macherey–Nagel) according to the manufac-
turer’s instructions. RNA concentration was measured 
using a NanoDrop 2000 spectrophotometer (Peqlab). RNA 
(0.1 µg) was reverse transcribed to cDNA using random 
primers (Roche) and Superscript III (Life Technologies). 
Quantitative real-time PCR was performed in a Rotor-
gene3000 (Corbett Research) using the Rotor-Gene SYBR 
Green PCR kit and the Quantitect primer assay HsQPCTL 
(Qiagen), or specific primers for HsCCL2, MsCCL2 and 
MsQPCTL synthesized by Metabion (Martinsried, Ger-
many) [8, 23]. Relative amounts of gene expression were 
determined with the Rotorgene software version 6.1 in 
comparative quantitation mode. Normalization was done 
against the most stably expressed reference gene YWHAZ 
identified using Normfinder [3]. The PCR was verified by 
product melting curves and single amplicons were con-
firmed by agarose gel electrophoresis.
Abeta and CCL2 ELISAs
Specific ELISAs to detect Abeta x-42 and pGlu-Abeta3-42 
(IBL, Hamburg) in human brain were performed as 
described by Schilling et al. [53]. CCL2 concentrations 
in mouse and human brain were quantified by ELISA 
(Thermo Scientific) as described earlier [8]. All samples 
were analyzed in triplicate and the concentrations of the 
respective Abeta peptides present in temporal cortex were 
calculated from a standard curve.
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IsoQC Western blot analyses
To analyze the amount of isoQC protein in mouse brain, 
immunoblotting was carried out. In initial experiments, 
four different anti-isoQC antibodies were tested for their 
specificity and sensitivity in brain tissue of wild-type, QC 
knock-out and isoQC knock-out mice. The antiserum 5407 
(Probiodrug, Halle/S., Germany) generated a specific band 
at the molecular weight of isoQC (43 kDa) when testing 
homogenates of wild-type and QC knock-out mice, but not 
isoQC knock-out mice (not shown). Tissue homogenates 
from cortex of wild-type and Tg2576 mice were loaded on 
a 12 % SDS polyacrylamide gel, separated by electropho-
resis and transferred onto polyvinylidene difluoride mem-
branes. The membranes were blocked overnight at 4 °C in 
TBS-T, pH 7.4, and 4 % BSA and subsequently incubated 
with primary rabbit anti-isoQC antibody 5407 (1:750) and 
with a secondary peroxidase-conjugated goat anti-rabbit 
antibody (1:1,000) for 1 h each. After washing the mem-
branes, the bound proteins were visualized by a luminol 
detection system (Santa Cruz). Normalization of isoQC 
expression was achieved after stripping and incubation in 
a mouse anti-β-actin antibody, 1:16,000 and subsequent 
detection by a secondary POD-conjugated donkey anti-
mouse antibody (1:10,000), followed by visualization with 
luminol detection system as described above. The blots 
were digitalized by the software GelCapture and the images 
were evaluated by densitometric image analysis using the 
software package TINA 2.0 (RAYTEST, Straubenhardt, 
Germany). The sum of gray values over each individual 
band obtained by densitometry was corrected for back-
ground and then the corrected values of the isoQC bands 
were compared to the corrected values of the β-actin bands.
Statistical analyses
Statistical analyses of qRT-PCR, ELISA and Western blot 
data were done by one-way ANOVA followed by Bonfer-
roni post hoc test. Statistically significant differences are 
given for p values of <0.05 (*), <0.01 (**) and <0.001 
(***) calculated using the unpaired t test with Welch’s cor-
rection. Correlation analyses of mRNA, ELISA and MMSE 
data were performed by calculating Pearson’s correlation 
coefficient r with GraphPad Prism4 software.
Results
IsoQC expression in mouse brain and co-localization 
with CCL2
In sagittal brain sections of 4-month-old mice, widespread 
isoQC immunoreactivity was observed in numerous brain 
regions from olfactory bulb to cerebellum and spinal cord 
(Fig. 1a). To determine the specificity of this unexpectedly 
abundant isoQC labeling, brain tissue of wild-type, isoQC 
knock-out and QC knock-out mice was analyzed. The labe-
ling generated by the isoQC antiserum 3285 in wild-type 
mouse brain was completely absent in isoQC knock-out but 
not in QC knock-out mouse brain tissue demonstrating the 
specificity of this antiserum for isoQC (Fig. 1b). In wild-
type mouse brain, significant proportions of neurons in 
neocortical (cingulate, frontal, parietal, piriform, entorhinal 
cortex), hippocampal (indusium griseum, cornu ammonis 
1–4, dentate gyrus) and subcortical (Edinger–Westphal 
nucleus, habenular and cochlear nucleus, locus coeruleus) 
brain structures were found to be isoQC-immunoreactive 
(Fig. 1c, d). The intensity of the isoQC labeling was strong-
est in hippocampal pyramidal, granular cells and indusium 
griseum, habenular, Edinger–Westphal nucleus, piriform 
and entorhinal cortex neurons (Fig. 1c, d).
In the unmanipulated 4-month-old mouse brain, the 
expression of isoQC was restricted to neurons as shown 
by co-localization with the neuronal marker HuC/D and 
by the absence of isoQC labeling in HuC/D-negative cells 
(Fig. 2a). Intracellularly, isoQC was present in endoplasmic 
reticulum and Golgi structures as shown by co-localization 
with calreticulin and with syntaxin-6, respectively 
(Fig. 2b). Neurons immunoreactive for isoQC frequently 
co-expressed its putative substrate CCL2 in mouse brain 
and in mouse primary neurons (Fig. 2c). The conversion of 
Gln-CCL2 by recombinant isoQC was analyzed applying 
a kinetic assay that is based on consumption of NADH in 
a coupled reaction [52] (Fig. 2d). The progress curve was 
in accordance with a curve modeled according to the inte-
grated form of the Michaelis–Menten equation, enabling 
the determination of the kinetic parameters KM and kcat. 
Fig. 4  Co-regulation of isoQC and CCL2 in mouse primary astro-
cytes upon Abeta stimulation. a Immunocytochemical double labe-
ling of isoQC (green) and CCL2 (red) with nuclear Hoechst coun-
terstaining (blue) under control conditions and after stimulation with 
Abeta (5 μM) or pGlu-Abeta (5 μM) as indicated. Note the robust 
increase in the immunocytochemical labeling intensity for both 
proteins at 24 and 48 h and the decline at 72 h. b Quantification of 
immunocytochemical labeling revealed a highly significant time- and 
Abeta peptide-specific increase in isoQC and CCL2 immunoreactiv-
ity. Correlation analyses between isoQC and CCL2 immunocyto-
chemical labeling demonstrated highly significant correlations in the 
expression of enzyme and substrate under control conditions (b1), 
after stimulation with Abeta (b2) and with pGlu-Abeta (b3). c Quan-
tification of isoQC and CCL2 mRNA expression under control condi-
tions and after stimulation with Abeta and pGlu-Abeta for different 
periods of time as indicated (N = 6 per time point). Note the absence 
of an increase of isoQC or CCL2 mRNA transcripts independent of 
the type and duration of the treatment. Correlation analyses of CCL2 
mRNA levels plotted versus isoQC mRNA levels in individual astro-
cyte culture wells under control conditions and after (pGlu)-Abeta 
stimulation including all time points analyzed. Note the absence of 
a correlation between enzyme and substrate mRNA expression under 
control (c1) and treatment conditions (c2, c3)
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The kinetic data show that CCL2 is converted by isoQC, 
but with lower efficiency compared to smaller peptide sub-
strates. The observed co-localization of isoQC and CCL2 
within intracellular compartments, i.e. at higher concentra-
tion of substrate and enzyme due to compartmentalization, 
might thus be important to facilitate the rather slow turno-
ver of CCL2.
Up-regulation of isoQC and CCL2 expression in APP 
transgenic Tg2576 mice
To reveal a possible effect of transgenic human APP 
expression and Abeta plaque formation on the expression 
of isoQC and its putative substrate CCL2, both transcripts 
were quantified in neocortex of 17-month-old wild-type 
and APP transgenic Tg2576 mice. The isoQC mRNA 
levels were increased by a factor of 2.35 in neocortex of 
Tg2576 mice compared to wild-type littermates (Fig. 3a). 
A statistically significant up-regulation by 55 % was also 
observed for CCL2 transcript levels in brains of Tg2576 
mice, indicating a pro-inflammatory response (Fig. 3a). 
The qRT-PCR data were validated by the demonstration of 
an up-regulation of GFAP mRNA, a well-known astrocytic 
response to Abeta plaque pathology (Fig. 3a).
The isoQC and pGlu-CCL2 protein levels quantified by 
Western blot analysis and ELISA, however, were not sig-
nificantly increased in cortex of Tg2576 mice compared to 
wild-type littermates (Fig. 3a). This is also illustrated by 
similar neuronal immunofluorescent labeling intensity for 
isoQC and for CCL2 in cortex of wild-type compared to 
Tg2576 mice (Fig. 3b).
However, with regard to the cell type-specific isoQC 
and CCL2 expression, we observed remarkable differences 
between aged wild-type and Tg2576 mice. While isoQC 
and CCL2 were neuron-specifically expressed in wild-
type mice, both proteins were additionally induced in neo-
cortical reactive astrocytes in proximity of Abeta plaques 
of 17-month-old Tg2576 mice (Fig. 3c, d). There was a 
gradient in the number of isoQC- and CCL2-immunoreac-
tive astrocytes per area from the plaque core towards the 
plaque periphery ranging from 21 isoQC- and 17 CCL2-
immunoreactive astrocytes, respectively, per 50,000 µm2 
in the core to 3 isoQC- and 2 CCL2-immunoreactive astro-
cytes per 50,000 µm2 in the periphery (Fig. 3c). This indi-
cates an Abeta-dependent mechanism of the induction of 
both proteins.
Simultaneous induction of isoQC and CCL2 in mouse 
primary astrocytes
Next, we were interested in establishing a cellular model 
that allows investigating the regulation of isoQC and CCL2 
in astrocytes. Therefore, mouse primary astrocytes were 
cultured and the mRNA and protein levels of isoQC and 
CCL2 were analyzed under control conditions and after 
stimulation with Abeta peptides, to mimic a pathogenic 
situation present at the sites of Abeta deposits in brains 
of Tg2576 mice and AD patients. Additionally, to reveal 
whether a general, non-AD-related inflammatory stimula-
tion induces astrocytic isoQC and CCL2 expression, astro-
cytes were also treated with LPS, IFN-γ, as well as a com-
bination of both substances, for different time periods.
While only weak immunocytochemical signals for 
isoQC and CCL2 protein were detected in untreated astro-
cytes, both proteins were transiently induced upon Abeta 
and pGlu-Abeta stimulation (Fig. 4a). CCL2 was maxi-
mally increased to 264 % (at 24 h of pGlu-Abeta stimula-
tion) and to 240 % (at 48 h of Abeta stimulation), respec-
tively, and declined to untreated control levels at 72 h after 
the onset of (pGlu)-Abeta treatment (Fig. 4b). The statisti-
cally significant induction of isoQC immunoreactivity was 
less pronounced after treatment with both Abeta variants 
but already present at 24 h and persisted until 72 h of treat-
ment (Fig. 4b). Correlation analyses between expression 
levels of isoQC and CCL2 in untreated cells (Fig. 4b1), 
Abeta-stimulated cells (Fig. 4b2) and pGlu-Abeta-stimu-
lated cells (Fig. 4b3) revealed a co-regulation of both pro-
teins under all experimental conditions. In these analyses, 
data from all time points of one type of treatment were 
pooled.
The increased isoQC and CCL2 protein levels detected 
are not based on elevated expression of the respective 
mRNAs as demonstrated by qRT-PCR (Fig. 4c). There 
were no correlations between isoQC and CCL2 transcript 
levels for any of the treatments performed (Fig. 4c1–3).
This is in contrast to findings following a general pro-
inflammatory challenge (LPS/IFN-γ stimulation), which 
revealed co-regulation of both isoQC and CCL2 transcript 
and protein expression in mouse primary astrocytes (see 
Supplementary Information 1).
Fig. 5  Immunohistological alterations of isoQC and CCL2 expres-
sion in AD cortex. a Immunohistochemistry for isoQC in human 
temporal cortex revealed a weak neuronal expression in control sub-
jects. In corresponding tissue sections of AD subjects, an increased 
neuronal labeling intensity, in particular in layer III pyramidal neu-
rons was observed. b A similar up-regulation in pyramidal layer III 
neurons was observed for CCL2. Additionally, both isoQC and CCL2 
were induced in glia-like cells in proximity of Abeta plaques (insets 
in a and b). c Triple immunofluorescent labelings of isoQC with 
CCL2 and GFAP identified these glial cells as astrocytes surround-
ing Abeta deposits. d The astrocytic expression of isoQC and CCL2 
in proximity of Abeta deposits followed a gradient from the core to 
the periphery of plaques (I, within plaque core diameter; II, double 
plaque core diameter; III, triple plaque core diameter). **p < 0.01, 
***p < 0.001
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IsoQC and CCL2 expression in human control and AD 
cortex
To reveal a possible role of isoQC and CCL2 in AD, immu-
nohistochemical labeling of human cortex from control and 
AD subjects was performed. In control tissue, a weak to 
moderate neuronal isoQC labeling across all cortical lay-
ers was observed (Fig. 5a). In contrast, a stronger neocorti-
cal isoQC labeling with the most robust staining intensity 
being present in layer III pyramidal neurons was detected 
in AD brain tissue (Fig. 5a). A similar labeling pattern and 
a higher staining intensity in layer III pyramidal neurons 
of AD subjects were also demonstrated for the isoQC sub-
strate CCL2 (Fig. 5b).
In AD brain tissue, both isoQC and CCL2 immunoreac-
tivity were detected in Abeta plaque-associated glial-like 
cells (insets in Fig. 5a, b). Based on the cellular morphol-
ogy and on observations made in Tg2576 mouse brain 
(compare Fig. 3d), we assumed these glial cells to be 
most likely astrocytes. To validate this presumption, triple 
immunofluorescent labelings of isoQC, CCL2 and GFAP 
on well-preserved human brain tissue were performed. 
The resulting co-localization clearly demonstrated the co-
induction of isoQC and CCL2 in Abeta plaque-associated 
reactive astrocytes (Fig. 5c) and supports the notion of an 
Abeta-driven inflammatory response involving isoQC-
mediated pGlu-CCL2 formation. Quantitative analysis 
of plaque-related astrocytic isoQC and CCL2 expression 
revealed a steeply decreasing density of immunoreactive 
astrocytes (number of astrocytes per 50,000 µm2) from 
13 isoQC- and 14 CCL2-expressing astrocytes per area in 
the plaque core, and 3 isoQC- and 4 CCL2-immunoreac-
tive astrocytes in the adjacent rim around the plaque to 2 
isoQC- and 2 CCL2-positive astrocytes in the outer rim 
most distant to the plaque, respectively (Fig. 5d). The 
Abeta plaque-associated expression of both proteins by 
reactive astrocytes was robust in 4 out of 6 and moderate 
in the remaining 2 AD cases. In controls, only one out of 6 
cases displayed isoQC and CCL2 immunoreactivity associ-
ated with discrete Abeta deposits.
In the second set of human brain tissue samples, quan-
titative biochemical and molecular biological analyses 
were performed with the aim (1) to validate a possible 
role of isoQC in pGlu-Abeta and pGlu-CCL2 formation 
in human brain and (2) to analyze biochemical alterations 
such as expression of isoQC as well as pGlu-Abeta and 
pGlu-CCL2 formation with regard to a possible associa-
tion with the clinical severity of AD as assessed by MMSE. 
To address this issue, pathologically and clinically well- 
characterized brain samples with a short postmortem interval 
were used (Table 2). By using qRT-PCR, an increase of 
isoQC mRNA levels to 235 ± 38 % and of CCL2 mRNA 
levels to 572 ± 139 % in AD temporal cortex compared 
to controls was detected (Fig. 6a; p < 0.05). Furthermore, 
the concentrations of CCL2 and pGlu-CCL2 in temporal 
cortex of control and AD cases were quantified by ELISA. 
Interestingly, pGlu-CCL2 accounted for more than 90 % 
of total CCL2 in both conditions. In controls, 193.6 pg/ml 
CCL2 and 205.6 pg/ml pGlu-CCL2 were detected, indicat-
ing complete conversion of CCL2 into its pGlu-modified 
variant. In postmortem brains from AD subjects, pGlu-
CCL2 levels were significantly higher than in control cases 
(Fig. 6a; p < 0.05) and represented 98.1 % of total CCL2 
(451.2 pg/ml CCL2 and 442.7 pg/ml pGlu-CCL2).
Correlation of isoQC and CCL2 with MMSE
To validate a possible role of isoQC in increased pGlu-
CCL2 formation in human brain as well as in cognitive 
decline in AD, a series of correlation analyses plotting bio-
chemical and clinical parameters from individual control 
and AD cases was performed.
Analyses revealed a strong correlation between 
increased levels of isoQC mRNA and low MMSE scores 
(r = −0.7220; p = 0.0080) and, similarly, between 
increased levels of CCL2 mRNA and low MMSE scores 
(r = −0.6124; p = 0.0343) (Fig. 6b, c).
However, correlation analysis revealed that there was no 
co-regulation of isoQC and CCL2 mRNA levels (Fig. 6d). 
Yet, CCL2 mRNA and protein levels displayed a strong 
positive correlation, validating the underlying measure-
ments of mRNA and protein concentrations (Fig. 6e). Just 
as high isoQC mRNA and CCL2 mRNA concentrations, 
high pGlu-CCL2 protein levels strongly correlated with a 
decline in MMSE (r = −0.6336; p = 0.0270) (Fig. 6f).
Additionally, we investigated a possible interrelation 
between the amount of isoQC mRNA and the accumula-
tion of Abeta and of pGlu-Abeta. While there was no cor-
relation between isoQC transcript levels and total Abeta42 
Fig. 6  Characteristics of isoQC, CCL2 and pGlu-Abeta accumu-
lation in AD and correlation analyses with MMSE. a Quantitative 
analyses revealed statistically significant increases of isoQC and 
CCL2 mRNA levels as well as pGlu-CCL2 protein in temporal cortex 
samples from AD cases compared to control subjects (*p < 0.05). b 
There was a statistically significant correlation between higher isoQC 
mRNA levels and the decline in MMSE (r = −0.7220; p = 0.0080). 
c Likewise, a statistically significant correlation between higher 
CCL2 mRNA levels and the decline in MMSE (r = −0.6124; 
p = 0.0343) was detected. d There was no correlation between isoQC 
and CCL2 transcript levels in the human brain samples analyzed. e 
A strong positive correlation between CCL2 mRNA and protein lev-
els was detected (r = 0.8552; p = 0.0004). f As for CCL2 mRNA, 
an inverse correlation between pGlu-CCL2 protein and MMSE was 
revealed (r = −0.6336; p = 0.0270). While there was no correlation 
between isoQC mRNA levels and total Abeta42 peptide concentra-
tions (g), a significant correlation between isoQC transcript levels and 
pGlu-Abeta concentrations was established (r = 0.6663; p = 0.0180) 
(h)
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concentrations (Fig. 6g), a strong correlation between 
elevated isoQC mRNA levels and increased pGlu-Abeta 
became evident (r = 0.6663; p = 0.0180) (Fig. 6h). This 
provides further evidence for a role of isoQC in pGlu-
Abeta formation, but not in Abeta generation in general.
Discussion
In the present study, the expression pattern of isoQC in 
mouse brain is reported for the first time and we provide 
evidence for an implication of isoQC-driven CCL2 expres-
sion and stabilization in chronic inflammation typical for 
brains of AD patients and APP transgenic mouse models.
Using a highly specific affinity-purified antiserum, a 
surprisingly wide-spread distribution of isoQC protein 
expression in mouse brain was demonstrated. In particu-
lar, distinct and neuron-specific isoQC immunoreactivity 
was detected in many neocortical, hippocampal, subcortical 
and cerebellar structures of normal wild-type mice. Since 
brain-specific functions and substrates of isoQC are not yet 
known, this observation was unexpected and calls for an 
investigation of biological functions of isoQC in brain. The 
differential substrate specificity of QC and isoQC appears 
to arise from their distinct subcellular localization and not 
from enzymatic characteristics. An example is the thyro-
tropin-releasing hormone (TRH) tripeptide Gln-His-Pro 
which is generated from its precursor during maturation by 
prohormone convertases 1 and 3 and carboxypeptidase E/D 
in secretory granules [7, 14] and, therefore, is purely a sub-
strate of QC, but not of Golgi-resident isoQC. On the other 
hand, the monocyte chemoattractant protein-1, CCL2, was 
demonstrated to be pGlu-modified and thus converted into 
a biologically active state in peripheral organs by isoQC, 
but not by QC [8].
The kinetic data shown here indicate that CCL2 is con-
verted by isoQC, but with lower efficiency compared to 
smaller peptide substrates. Based on these experimen-
tal observations and on the reported role of CCL2 in AD 
[58, 60], we here addressed a possible interrelationship of 
isoQC and CCL2 in brain. Indeed, double immunofluores-
cent labeling revealed a co-localization of both proteins in 
mouse brain neurons and in cultured primary neurons. This 
co-localization of isoQC and CCL2 within intracellular 
compartments, i.e. at higher concentration of substrate and 
enzyme due to compartmentalization, might be important 
to facilitate the rather slow turnover of CCL2.
We also observed an up-regulation of isoQC and CCL2 
mRNA levels and the induction of the enzyme isoQC and its 
putative substrate CCL2 in reactive astrocytes in proximity 
of Abeta plaques in Tg2576 mice. Interestingly, this astro-
cytic co-induction of both proteins followed a gradient 
from the plaque core towards the periphery, which suggests 
an Abeta-dependent mechanism. This co-induction of both 
proteins in the same cell type is indicative of a coordinated 
inflammatory response to recruit peripheral blood mono-
cytes and other immune cells to loci of pathogenic pro-
tein aggregation. The resulting chronic gliosis may also 
contribute to aspects of AD pathology and to a decline in 
cognitive performance, a notion which is supported by a 
previous pharmacological treatment study. When young 
APP transgenic Tg2576 mice were treated with an inhibi-
tor of QC/isoQC, pGlu-Abeta formation, total Abeta load 
and gliosis were reduced and memory deficits were amelio-
rated [53]. This is consistent with the view that prevention 
of pathogenic pGlu-Abeta seed formation has specific anti-
inflammatory and mnemonic effects. However, when this 
pharmacological treatment was initiated in older mice—i.e. 
after initial pGlu-Abeta seed formation had already taken 
place—the total Abeta plaque load was not reduced, but 
accompanying microgliosis was ameliorated and context 
fear memory was improved in aged Tg2576 mice [53]. We 
hypothesize that the effects observed in this study can be 
attributed at least in part to inhibition of isoQC. Reduced 
enzymatic activity may then result in lowered astrocytic 
CCL2 pGlu modification, minimized CCL2 biological 
activity, alleviated microglial recruitment and diminished 
pro-inflammatory response, which collectively may lead to 
improved performance in the cognitive tasks tested. This 
scenario would be in line with recent studies demonstrat-
ing that an inhibitor of CCL2 synthesis protects neurons 
against Abeta toxicity [57] and that inhibition of microglial 
activation reduces cognitive deficits in a transgenic mouse 
model for AD [5].
The induction of AD-related proteins in reactive astro-
cytes following a number of challenges was consistently 
reported in the past for APP, BACE1 and γ-secretase com-
ponents [17, 37, 64] and is expanded here to isoQC and 
its substrate CCL2. To corroborate this finding, we used a 
primary astrocyte model to study aspects of isoQC/CCL2 
regulation under conditions of Abeta pathology. As a stimu-
lation model, Abeta and pGlu-Abeta peptides were applied 
to astrocytic cultures. We observed a co-induction of both 
isoQC and CCL2 on the protein but not on the mRNA 
level. Under these conditions, there was a strong correla-
tion between isoQC and CCL2 protein expression in indi-
vidual culture wells, which was not observed for the tran-
script level. Thus, this model appears to be useful to study 
regulatory mechanisms of isoQC and CCL2 co-induction 
in astroglial cells. Additionally, astrocytes and microglia—
but not neurons—were recently reported to be the source of 
N-terminally truncated Abeta peptides, another pathogenic 
QC/isoQC substrate [39].
Some of the observations made in APP transgenic 
Tg2576 mice were mirrored in brains of AD patients. In 
immunohistochemically processed sections of the temporal 
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neocortex, a robust expression of isoQC in pyramidal neu-
rons was conspicuous and much less pronounced in con-
trol cases. Additionally, isoQC was expressed by reactive 
astrocytes which also displayed CCL2 immunoreactivity 
in proximity to Abeta deposits. This indicates that simi-
lar mechanisms of isoQC and CCL2 regulation are active 
in the diseased human brain and in the transgenic mouse 
model analyzed. It is important to note that isoQC and 
CCL2 proteins were not detected in activated microglial 
cells of APP transgenic Tg2576 mice and AD subjects (data 
not shown).
Next, we sought to correlate the cognitive status of 
elderly humans with isoQC expression levels and pGlu-
CCL2 protein levels in brain to assess the clinical signifi-
cance of our findings. To address this issue, isoQC expres-
sion was quantified in temporal cortex (Brodmann Area 
22), a part of the associative cortex involved in language 
processing [48]. Brain tissue with a very short postmortem 
delay and a well-documented clinical status was received 
from the Banner Health Brain Donation Program. Bio-
chemical and molecular biological analyses included qRT-
PCR to detect isoQC and CCL2 mRNAs as well as ELISA 
to quantify pGlu-Abeta and pGlu-CCL2 protein concen-
trations. Matching our immunohistochemical data, isoQC 
transcript levels were shown to be elevated in AD temporal 
cortex, as were total Abeta42 and pGlu-Abeta peptide con-
centrations and pGlu-CCL2 levels.
For individual cases, mRNA and protein measure-
ments were correlated with the respective cognitive 
status as measured by MMSE. Here, a good correla-
tion between isoQC mRNA levels and the concentration 
of pGlu-CCL2 was detected, supporting the notion of 
isoQC-catalyzed pGlu-CCL2 formation in human cortex 
contributing to pathological events. However, since only 
end-stage AD cases were analyzed in this study, it is not 
possible to draw conclusions on the sequence of events 
taking place. There were also strong inverse correlations 
between CCL2 mRNA and pGlu-CCL2 protein concen-
trations and MMSE. This is not surprising since neuroin-
flammatory events are characteristic of AD. On the other 
hand, CCL2 signaling is known to be enhanced in breast 
cancer, a condition present in the case AD3 of our cohort, 
which displays particularly high pGlu-CCL2 levels. Thus, 
the issue of possible co-morbidities should be addressed 
in further studies with larger cohorts. Taken together, this 
study points towards a specific role of isoQC and pGlu-
CCL2 in cognitive decline in AD and underlines the thera-
peutic potential of targeting the generation of pGlu-CCL2 
by inhibition of isoQC. Additionally, isoQC mRNA levels, 
but not QC mRNA concentrations inversely correlated 
with MMSE.
In recent studies, we have demonstrated a tight asso-
ciation between QC expression and pGlu-Abeta formation 
in hippocampus [15] and neocortex of AD patients [36]. 
There were strong correlations between QC mRNA levels 
and pGlu-Abeta concentrations and between pGlu-Abeta 
accumulation and a decline in MMSE [36]. Here, we 
expand these findings and provide additional evidence for 
a contribution of isoQC in pathogenic protein aggregation, 
neuroinflammation and cognitive decline in AD.
Based on the documented role of isoQC in peripheral 
inflammatory processes reported earlier and on the pro-
inflammatory function of isoQC in brain demonstrated here 
for the first time, these findings point towards a critical 
role of inflammation in cognitive decline in AD. Together, 
our observations provide evidence for a dual involvement 
of QCs in AD pathogenesis by QC- and isoQC-catalyzed 
pGlu-Abeta formation and by isoQC-driven CCL2 stabili-
zation maintaining chronic inflammatory events which col-
lectively affect cognition.
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